Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gunasekaran Kannan is active.

Publication


Featured researches published by Gunasekaran Kannan.


Molecular Immunology | 2013

IgG2 disulfide isoform conversion kinetics

Yaoqing Diana Liu; Tian Wang; Robert Y.-T. Chou; Louise Chen; Gunasekaran Kannan; Riki Stevenson; Andrew M. Goetze; Xinzhao Grace Jiang; Gang Huang; Thomas M. Dillon; Gregory C. Flynn

Human IgG2 antibodies contain three types of disulfide isoforms, classified by the number of Fab arms having disulfide links to the heavy chain hinge region. In the IgG2-B form, both Fab arms have interchain disulfide bonds to the hinge region, and in IgG2-A, neither Fab arm are disulfide linked to the hinge. The IgG2-A/B is a hybrid between these two forms, with only one Fab arm disulfide linked to the hinge. Changes in the relative levels of these forms over time are observed while IgG2 circulates in humans, suggesting IgG2-A→IgG2-A/B→IgG2-B conversion. Using a flow-through dialysis system, we studied the conversion kinetics of these forms in vitro under physiological conditions. For two IgG2κ antibodies, in vivo results closely matched the kinetics observed in vitro, indicating that the changes observed in vivo were solely conversions between isoforms, not differential clearance of specific forms. Moreover, the combined results validate the accuracy of the physiological model for the study of blood redox reactions. Further exploration of the conversion kinetics using material enriched in the IgG2-A forms revealed that the IgG2-A→IgG2-A/B rate was similar between IgG2κ and IgG2λ antibodies. In IgG2κ antibodies, conversion of IgG2-A/B→IgG2-B was slower than the IgG2-A→IgG2-A/B reaction. However, in IgG2λ antibodies, little IgG2-A/B→IgG2-B conversion was detected under physiological conditions. Thus, small differences in the C-terminus of the light chain sequences affect the disulfide conversion kinetics and impact the IgG2 disulfide isoforms produced in vivo.


Archive | 2009

Method for making antibody fc-heterodimeric molecules using electrostatic steering effects

Gunasekaran Kannan; Michael Wittekind; Wei Yan; Martin J. Pentony


Archive | 2010

Monomeric antibody fc

Gunasekaran Kannan; Hongxing Zhou; Nancy Sun


Archive | 2010

DESIGN OF STABLE AND AGGREGATION FREE ANTIBODY FC MOLECULES THROUGH CH3 DOMAIN INTERFACE ENGINEERING

Gunasekaran Kannan; Hongxing Zhou


Archive | 2013

GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES

Yumei Xiong; Yi Zhang; Jackie Zeqi Sheng; Agnes Eva Hamburger; Murielle Veniant-Ellison; Grant Shimamoto; Xiaoshan Min; Zhulun Wang; Jie Tang; Gunasekaran Kannan; Kenneth W. Walker; Bryan Lemon


Archive | 2014

Interleukin-2 muteins for the expansion of t-regulatory cells

Marc A. Gavin; Gunasekaran Kannan; Li Li; Joshua T. Pearson; Margaret Karow


Archive | 2012

METHOD OF CORRELATED MUTATIONAL ANALYSIS TO IMPROVE THERAPEUTIC ANTIBODIES

Gunasekaran Kannan


Archive | 2014

Growth differentiation factor 15 (gdf-15) constructs

Yumei Xiong; Yi Zhang; Jackie Zeqi Sheng; Agnes Eva Hamburger; Murielle Veniant-Ellison; Grant Shimamoto; Xiaoshan Min; Zhulun Wang; Jie Tang; Gunasekaran Kannan; Marissa Mock; Kenneth W. Walker


Archive | 2013

Bcma antigen binding proteins

Richard J. Armitage; Michelle Blake; Iii William Christian Fanslow; Jason C. O'neill; Gunasekaran Kannan; Jiangchun Xu; Mark E. Tometsko; Zhulun Wang; Athena Sudom


Archive | 2014

PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF

Hailing Hsu; Ming Zhang; Gunasekaran Kannan; Frederick W. Jacobsen; Wayne Tsuji

Researchain Logo
Decentralizing Knowledge